Adjuvant therapy in pancreatic cancer
- PMID: 25356036
- PMCID: PMC4209539
- DOI: 10.3748/wjg.v20.i40.14733
Adjuvant therapy in pancreatic cancer
Abstract
Pancreatic cancer remains one of the leading causes of cancer related death worldwide with an overall five-year survival of less than 5%. Potentially curative surgery, which alone can improve 5-year survival to 10%, is an option for only 10%-20% of patients at presentation owing to local invasion of the tumour or metastatic disease. Adjuvant chemotherapy has been shown to improve 5-year survival to 20%-25% but conflicting evidence remains with regards to chemoradiation. In this article we review the current evidence available from published randomised trials and discuss ongoing phase III trials in relation to adjuvant therapy in pancreatic cancer.
Keywords: Adjuvant; Chemoradiotherapy; Chemotherapy; Gemcitabine; Pancreatic cancer; Phase III.
References
-
- Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. - PubMed
-
- Available from: http://www.wcrf.org/cancer_statistics/world_cancer_statistics.php.
-
- Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Büchler MW. Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg. 2004;91:586–594. - PubMed
-
- Zimmerman SE, Smith FP, Schein PS. Chemotherapy of pancreatic carcinoma. Cancer. 1981;47:1724–1728. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
